Document:

<PAGE>

                                 EXHIBIT 10.20
                       AMENDMENT AND RESTATEMENT OF THE

                                  ARCA CORP.

                          1999 DUAL STOCK OPTION PLAN

                           As Adopted July 24, 2001

     The Board of Directors of Agate Technologies, Inc. hereby amends and
restates in its entirety the ARCA CORP. 1999 Dual Stock Option Plan as follows:

1.   NAME.

     The name of the plan shall be changed from "ARCA CORP. 1999 Dual Stock
Option Plan" to "Agate Technologies, Inc. Equity Incentive Plan".

2.   PURPOSE.

     The purpose of this Plan is to provide incentives to attract, retain and
motivate eligible persons whose present and potential contributions are
important to the success of the Company, and its Parent and Subsidiaries (if
any), by offering them an opportunity to participate in the Company's future
performance through awards of Options, Restricted Stock and Stock Bonuses.
Capitalized terms not defined in the text are defined in Section 3.

3.   DEFINITIONS.

     As used in this Plan, the following terms will have the following meanings:

     "AWARD" means any award under this Plan, including any Option, Restricted
      -----
Stock or Stock Bonus.

     "AWARD AGREEMENT" means, with respect to each Award, the signed written
      ---------------
agreement between the Company and the Participant setting forth the terms and
conditions of the Award.

     "BOARD" means the Board of Directors of the Company.
      -----

     "CAUSE" means any cause, as defined by applicable law, for the termination
      -----
of a Participant's employment with the Company or a Parent or Subsidiary of the
Company.

     "CODE" means the Internal Revenue Code of 1986, as amended.
      ----

     "COMMITTEE" means the Board of Directors.
      ---------
<PAGE>

     "COMPANY" means Agate Technologies, Inc., a Delaware corporation, or any
      -------
successor corporation.

     "DISABILITY" means a disability, whether temporary or permanent, partial or
      ----------
total, as determined by the Committee.

     "EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended.
      ------------

     "EXERCISE PRICE" means the price at which a holder of an Option may
      --------------
purchase the Shares issuable upon exercise of the Option.

     "FAIR MARKET VALUE" means, as of any date, the value of a share of the
      -----------------
Company's Common Stock determined as follows:

          (a) if such Common Stock is publicly traded and is then listed on a
     national securities exchange, its closing price on the date of
     determination on the principal national securities exchange on which the
     Common Stock is listed or admitted to trading as reported in The Wall
     Street Journal;

          (b) if such Common Stock is quoted on the NASDAQ National Market, its
     closing price on the NASDAQ National Market on the date of determination as
     reported in The Wall Street Journal;

          (c) if such Common Stock is publicly traded but is not listed or
     admitted to trading on a national securities exchange, the average of the
     closing bid and asked prices on the date of determination as reported in
     The Wall Street Journal;

          (d) the price per share at which shares of the Company's Common Stock
     are initially offered for sale to the public by the Company's underwriters
     in the initial public offering of the Company's Common Stock pursuant to a
     registration statement filed with the SEC under the Securities Act if the
     Award is made on the effective date of such registration statement; or

          (e) if none of the foregoing is applicable, by the Committee in good
     faith.

     "INSIDER" means an officer or director of the Company or any other person
      -------
whose transactions in the Company's Common Stock are subject to Section 16 of
the Exchange Act.

     "OPTION" means an award of an option to purchase Shares pursuant to Section
      ------
7.

     "PARENT" means any corporation (other than the Company) in an unbroken
      ------
chain of corporations ending with the Company if each of such corporations other
than
<PAGE>

the Company owns stock possessing 50% or more of the total combined voting power
of all classes of stock in one of the other corporations in such chain.

     "PARTICIPANT" means a person who receives an Award under this Plan.
      -----------

     "PERFORMANCE FACTORS" means the factors selected by the Committee, in its
      -------------------
sole and absolute discretion, from among the following measures to determine
whether the performance goals applicable to Awards have been satisfied:

          (a)  Net revenue and/or net revenue growth;

          (b)  Earnings before income taxes and amortization and/or earnings
               before income taxes and amortization growth;

          (c)  Operating income and/or operating income growth;

          (d)  Net income and/or net income growth;

          (e)  Earnings per share and/or earnings per share growth;

          (f)  Total stockholder return and/or total stockholder return growth;

          (g)  Return on equity;

          (h)  Operating cash flow return on income;

          (i)  Adjusted operating cash flow return on income;

          (j)  Economic value added; and

          (k)  Individual business objectives.

     "PERFORMANCE PERIOD" means the period of service determined by the
      ------------------
Committee, not to exceed five years, during which years of service or
performance is to be measured for Restricted Stock Awards or Stock Bonuses.

     "PLAN" means this Agate Technologies, Inc. Equity Incentive Plan, as
      ----
amended from time to time.

     "RESTRICTED STOCK AWARD" means an award of Shares pursuant to Section 8.
      ----------------------

     "SEC" means the Securities and Exchange Commission.
      ---

     "SECURITIES ACT" means the Securities Act of 1933, as amended.
      --------------
<PAGE>

     "SHARES" means shares of the Company's Common Stock reserved for issuance
      ------
under this Plan, as adjusted pursuant to Sections 4 and 19, and any successor
security.

     "STOCK BONUS" means an award of Shares, or cash in lieu of Shares, pursuant
      -----------
to Section 9.

     "SUBSIDIARY" means any corporation (other than the Company) in an unbroken
      ----------
chain of corporations beginning with the Company if each of the corporations
other than the last corporation in the unbroken chain owns stock possessing 50%
or more of the total combined voting power of all classes of stock in one of the
other corporations in such chain.

     "TERMINATION" or "TERMINATED" means, for purposes of this Plan with respect
      -----------      ----------
to a Participant, that the Participant has for any reason ceased to provide
services as an employee, officer, director, consultant, independent contractor,
or advisor to the Company or a Parent or Subsidiary of the Company.  An employee
will not be deemed to have ceased to provide services in the case of (i) sick
leave, (ii) military leave, or (iii) any other leave of absence approved by the
Company, provided that such leave is for a period of not more than 90 days,
unless reemployment upon the expiration of such leave is guaranteed by contract
or statute or unless provided otherwise pursuant to a formal policy adopted from
time to time by the Company and issued and promulgated to employees in writing.
In the case of any employee on an approved leave of absence, the Committee may
make such provisions respecting suspension of vesting of the Award while on
leave from the employ of the Company or a Subsidiary as it may deem appropriate,
except that in no event may an Option be exercised after the expiration of the
term set forth in the Option agreement.  The Committee will have sole discretion
to determine whether a Participant has ceased to provide services and the
effective date on which the Participant ceased to provide services (the
"Termination Date").

4.   SHARES SUBJECT TO THE PLAN.

     4.1  Number of Shares Available.  At no time shall the total number of
          --------------------------
shares issuable upon exercise of all outstanding Awards exceed the applicable
percentage as calculated in accordance with the conditions and exclusions of
Regulation 260.140.45 of Title 10 of the California Code of Regulations, based
on the shares of the Company's Common Stock which are outstanding at the time
the calculation is made.  Subject to Sections 4.2 and 19, the total aggregate
number of Shares reserved and available for grant and issuance pursuant to this
Plan will be 4,500,000 Shares and will include Shares that are subject to:  (a)
issuance upon exercise of an Option but cease to be subject to such Option for
any reason other than exercise of such Option; (b) an Award granted hereunder
but forfeited or repurchased by the Company at the original issue price; and (c)
an Award that otherwise terminates without Shares being issued.  (This number is
not meant to increase the number of shares subject to the ARCA CORP. 1999 Dual
Stock Option Plan.  Instead, it represents the number of shares originally
subject to the ARCA CORP. 1999 Dual Stock Option Plan, reduced by all awards
made pursuant to that plan.)
<PAGE>

At all times the Company shall reserve and keep available a sufficient number of
Shares as shall be required to satisfy the requirements of all outstanding
Options granted under this Plan and all other outstanding but unvested Awards
granted under this Plan.

     4.2  Adjustment of Shares.  In the event that the number of outstanding
          --------------------
shares is changed by a stock dividend, recapitalization, stock split, reverse
stock split, subdivision, combination, reclassification or similar change in the
capital structure of the Company without consideration, then (a) the number of
Shares reserved for issuance under this Plan, (b) the Exercise Prices of and
number of Shares subject to outstanding Options, and (c) the number of Shares
subject to other outstanding Awards will be proportionately adjusted, subject to
any required action by the Board or the stockholders of the Company and
compliance with applicable securities laws; provided, however, that fractions of
a Share will not be issued but will either be replaced by a cash payment equal
to the Fair Market Value of such fraction of a Share or will be rounded up to
the nearest whole Share, as determined by the Committee.

5.   ELIGIBILITY.

     ISOs (as defined in Section 7 below) may be granted only to employees
(including officers and directors who are also employees) of the Company or of a
Parent or Subsidiary of the Company.  All other Awards may be granted to
employees, officers, directors, consultants, independent contractors and
advisors of the Company or any Parent or Subsidiary of the Company, provided
such consultants, contractors and advisors render bona fide services not in
connection with the offer and sale of securities in a capital-raising
transaction.  A person may be granted more than one Award under this Plan.

6.   ADMINISTRATION.

     6.1  Committee Authority.  This Plan will be administered by the Committee
          -------------------
or by the Board acting as the Committee.  Subject to the general purposes, terms
and conditions of this Plan, and to the direction of the Board, the Committee
will have full power to implement and carry out this Plan.  Without limitation,
the Committee will have the authority to:

          (a) construe and interpret this Plan, any Award Agreement and any
other agreement or document executed pursuant to this Plan;

          (b) prescribe, amend and rescind rules and regulations relating to
this Plan or any Award;

          (c) select persons to receive Awards;

          (d) determine the form and terms of Awards;
<PAGE>

          (e) determine the number of Shares or other consideration subject to
Awards;

          (f) determine whether Awards will be granted singly, in combination
with, in tandem with, in replacement of, or as alternatives to, other Awards
under this Plan or any other incentive or compensation plan of the Company or
any Parent or Subsidiary of the Company;

          (g) grant waivers of Plan or Award conditions;

          (h) determine the vesting, exercisability and payment of Awards;

          (i) correct any defect, supply any omission or reconcile any
inconsistency in this Plan, any Award or any Award Agreement;

          (j) determine whether an Award has been earned; and

          (k) make all other determinations necessary or advisable for the
administration of this Plan.

     6.2  Committee Discretion.  Any determination made by the Committee with
          --------------------
respect to any Award will be made at the time of grant of the Award or, unless
in contravention of any express term of this Plan or Award, at any later time,
and such determination will be final and binding on the Company and on all
persons having an interest in any Award under this Plan.  The Committee may
delegate to one or more officers of the Company the authority to grant an Award
under this Plan to Participants who are not Insiders of the Company.

7.   OPTIONS.

     The Committee may grant Options to eligible persons and will determine
whether such Options will be Incentive Stock Options within the meaning of the
Code ("ISO") or Nonqualified Stock Options ("NQSOs"), the number of Shares
subject to the Option, the Exercise Price of the Option, the period during which
the Option may be exercised, and all other terms and conditions of the Option,
subject to the following:

     7.1  Form of Option Grant.  Each Option granted under this Plan will be
          --------------------
evidenced by an Award Agreement which will expressly identify the Option as an
ISO or an NQSO (hereinafter referred to as the "Stock Option Agreement"), and
will be in such form and contain such provisions (which need not be the same for
each Participant) as the Committee may from time to time approve, and which will
comply with and be subject to the terms and conditions of this Plan.
<PAGE>

     7.2  Date of Grant.  The date of grant of an Option will be the date on
          -------------
which the Committee makes the determination to grant such Option, unless
otherwise specified by the Committee.  The Stock Option Agreement and a copy of
this Plan will be delivered to the Participant within a reasonable time after
the granting of the Option.

     7.3  Exercise Period.  Options may be exercisable within the times or upon
          ---------------
the events determined by the Committee as set forth in the Stock Option
Agreement governing such Option; provided, however, that no Option will be
exercisable after the expiration of ten (10) years from the date the Option is
granted; and provided further that no ISO granted to a person who directly or by
attribution owns more than ten percent (10%) of the total combined voting power
of all classes of stock of the Company or of any Parent or Subsidiary of the
Company ("Ten Percent Stockholder") will be exercisable after the expiration of
five (5) years from the date the ISO is granted.  The Committee also may provide
for Options to become exercisable at one time or from time to time, periodically
or otherwise, in such number of Shares or percentage of Shares as the Committee
determines.

     7.4  Exercise Price.  The Exercise Price of an Option will be determined by
          --------------
the Committee when the Option is granted and may be not less than 85% of the
Fair Market Value of the Shares on the date of grant; provided that:  (a) the
Exercise Price of an ISO will be not less than 100% of the Fair Market Value of
the Shares on the date of grant; and (b) the Exercise Price of any ISO granted
to a Ten Percent Stockholder will not be less than 110% of the Fair Market Value
of the Shares on the date of grant.  Payment for the Shares purchased may be
made in accordance with Section 10 of this Plan.

     7.5  Method of Exercise.  Options may be exercised only by delivery to the
          ------------------
Company of a written stock option exercise agreement  (the "Exercise Agreement")
in a form approved by the Committee, (which need not be the same for each
Participant), stating the number of Shares being purchased, the restrictions
imposed on the Shares purchased under such Exercise Agreement, if any, and such
representations and agreements regarding the Participant's investment intent and
access to information and other matters, if any, as may be required or desirable
by the Company to comply with applicable securities laws, together with payment
in full of the Exercise Price for the number of Shares being purchased.

     7.6  Termination.  Notwithstanding the exercise periods set forth in the
          -----------
Stock Option Agreement, exercise of an Option will always be subject to the
following:

          (a) If the Participant's service is Terminated for any reason except
death or Disability, then the Participant may exercise such Participant's
Options only to the extent that such Options would have been exercisable upon
the Termination Date no later than three (3) months after the Termination Date
(or such shorter or longer time period not exceeding five (5) years as may be
determined by the Committee, with any exercise beyond three (3) months after the
Termination Date deemed to be an NQSO), but in any event, no later than the
expiration date of the Options.
<PAGE>

          (b) If the Participant's service is Terminated because of the
Participant's death or Disability (or the Participant dies within three (3)
months after a Termination other than for Cause or because of Participant's
Disability), then the Participant's Options may be exercised only to the extent
that such Options would have been exercisable by the Participant on the
Termination Date and must be exercised by the Participant (or the Participant's
legal representative) no later than twelve (12) months after the Termination
Date (or such shorter or longer time period not exceeding five (5) years as may
be determined by the Committee, with any such exercise beyond (i) three (3)
months after the Termination Date when the Termination is for any reason other
than the Participant's death or Disability, or (ii) twelve (12) months after the
Termination Date when the Termination is for Participant's death or Disability,
deemed to be an NQSO), but in any event no later than the expiration date of the
Options.

          (c) Notwithstanding the provisions in paragraph 7.6(a) above, if the
Participant's service is Terminated for Cause, neither the Participant, the
Participant's estate nor such other person who may then hold the Option shall be
entitled to exercise any Option with respect to any Shares whatsoever, after
Termination, whether or not after Termination the Participant may receive
payment from the Company or a Subsidiary for vacation pay, for services rendered
prior to Termination, for services rendered for the day on which Termination
occurs, for salary in lieu of notice, or for any other benefits.  For the
purpose of this paragraph, Termination shall be deemed to occur on the date when
the Company dispatches notice or advice to the Participant that his service is
Terminated.

     7.7  Limitations on Exercise.  The Committee may specify a reasonable
          -----------------------
minimum number of Shares that may be purchased on any exercise of an Option,
provided that such minimum number will not prevent the Participant from
exercising the Option for the full number of Shares for which it is then
exercisable.

     7.8  Limitations on ISO.  The aggregate Fair Market Value (determined as of
          ------------------
the date of grant) of Shares with respect to which ISO are exercisable for the
first time by a Participant during any calendar year (under this Plan or under
any other incentive stock option plan of the Company, Parent or Subsidiary of
the Company) will not exceed $100,000.  If the Fair Market Value of Shares on
the date of grant with respect to which ISO are exercisable for the first time
by a Participant during any calendar year exceeds $100,000, then the Options for
the first $100,000 worth of Shares to become exercisable in such calendar year
will be ISO and the Options for the amount in excess of $100,000 that become
exercisable in that calendar year will be NQSOs.  In the event that the Code or
the regulations promulgated thereunder are amended after the Effective Date of
this Plan to provide for a different limit on the Fair Market Value of Shares
permitted to be subject to ISO, such different limit will be automatically
incorporated herein and will apply to any Options granted after the effective
date of such amendment.

     7.9  Modification, Extension or Renewal.  The Committee may modify, extend
          ----------------------------------
or renew outstanding Options and authorize the grant of new Options in
substitution therefore, provided that any such action may not, without the
written consent of a
<PAGE>

Participant, impair any of such Participant's rights under any Option previously
granted. Any outstanding ISO that is modified, extended, renewed or otherwise
altered will be treated in accordance with Section 424(h) of the Code. The
Committee may reduce the Exercise Price of outstanding Options without the
consent of Participants affected by a written notice to them; provided, however,
that the Exercise Price may not be reduced below the minimum Exercise Price that
would be permitted under Section 7.4 of this Plan for Options granted on the
date the action is taken to reduce the Exercise Price.

     7.10 No Disqualification.  Notwithstanding any other provision in this
          -------------------
Plan, no term of this Plan relating to ISO will be interpreted, amended or
altered, nor will any discretion or authority granted under this Plan be
exercised, so as to disqualify this Plan under Section 422 of the Code or,
without the consent of the Participant affected, to disqualify any ISO under
Section 422 of the Code.

8.   RESTRICTED STOCK.

     A Restricted Stock Award is an offer by the Company to sell to an eligible
person Shares that are subject to restrictions.  The Committee will determine to
whom an offer will be made, the number of Shares the person may purchase, the
price to be paid (the "Purchase Price"), the restrictions to which the Shares
will be subject, and all other terms and conditions of the Restricted Stock
Award, subject to the following:

     8.1  Form of Restricted Stock Award.  All purchases under a Restricted
          ------------------------------
Stock Award made pursuant to this Plan will be evidenced by an Award Agreement
(the "Restricted Stock Purchase Agreement") that will be in such form (which
need not be the same for each Participant) as the Committee will from time to
time approve, and will comply with and be subject to the terms and conditions of
this Plan.  The offer of Restricted Stock will be accepted by the Participant's
execution and delivery of the Restricted Stock Purchase Agreement and full
payment for the Shares to the Company within thirty (30) days from the date the
Restricted Stock Purchase Agreement is delivered to the person.  If such person
does not execute and deliver the Restricted Stock Purchase Agreement along with
full payment for the Shares to the Company within thirty (30) days, then the
offer will terminate, unless otherwise extended by the Committee.

     8.2  Purchase Price.  The Purchase Price of Shares sold pursuant to a
          --------------
Restricted Stock Award will be determined by the Committee on the date the
Restricted Stock Award is granted and may not be less than 85% of the Fair
Market Value of the Shares on the grant date, except in the case of a sale to a
Ten Percent Stockholder, in which case the Purchase Price will be 100% of the
Fair Market Value.  Payment of the Purchase Price must be made in accordance
with Section 10 of this Plan.

     8.3  Terms of Restricted Stock Awards.  Restricted Stock Awards shall be
          --------------------------------
subject to such restrictions as the Committee may impose.  These restrictions
may be based upon completion of a specified number of years of service with the
Company or upon completion of the performance goals as set out in advance in the
Participant's
<PAGE>

individual Restricted Stock Purchase Agreement. Restricted Stock Awards may vary
from Participant to Participant and between groups of Participants. Prior to the
grant of a Restricted Stock Award, the Committee shall: (a) determine the
nature, length and starting date of any Performance Period for the Restricted
Stock Award; (b) select from among the Performance Factors to be used to measure
performance goals, if any; and (c) determine the number of Shares that may be
awarded to the Participant. Prior to the payment of any Restricted Stock Award,
the Committee shall determine the extent to which such Restricted Stock Award
has been earned. Performance Periods may overlap and Participants may
participate simultaneously with respect to Restricted Stock Awards that are
subject to different Performance Periods and have different performance goals
and other criteria.

     8.4  Termination During Performance Period.  If a Participant is Terminated
          -------------------------------------
during a Performance Period for any reason, then such Participant will be
entitled to payment (whether in Shares, cash or otherwise) with respect to the
Restricted Stock Award only to the extent earned as of the date of Termination
in accordance with the Restricted Stock Purchase Agreement, unless the Committee
determines otherwise.

9.   STOCK BONUSES.

     9.1  Awards of Stock Bonuses.  A Stock Bonus is an award of Shares (which
          -----------------------
may consist of Restricted Stock) for extraordinary services rendered to the
Company or any Parent or Subsidiary of the Company.  A Stock Bonus will be
awarded pursuant to an Award Agreement (the "Stock Bonus Agreement") that will
be in such form (which need not be the same for each Participant) as the
Committee will from time to time approve, and will comply with and be subject to
the terms and conditions of this Plan.  A Stock Bonus may be awarded upon
satisfaction of such performance goals as are set out in advance in the
Participant's individual Award Agreement (the "Performance Stock Bonus
Agreement") that will be in such form (which need not be the same for each
Participant) as the Committee will from time to time approve, and will comply
with and be subject to the terms and conditions of this Plan.  Stock Bonuses may
vary from Participant to Participant and between groups of Participants, and may
be based upon the achievement of the Company, Parent or Subsidiary and/or
individual performance factors or upon such other criteria as the Committee may
determine.

     9.2  Terms of Stock Bonuses.  The Committee will determine the number of
          ----------------------
Shares to be awarded to the Participant.  If the Stock Bonus is being earned
upon the satisfaction of performance goals pursuant to a Performance Stock Bonus
Agreement, then the Committee will: (a) determine the nature, length and
starting date of any Performance Period for each Stock Bonus; (b) select from
among the Performance Factors to be used to measure the performance, if any; and
(c) determine the number of Shares that may be awarded to the Participant.
Prior to the payment of any Stock Bonus, the Committee shall determine the
extent to which such Stock Bonuses have been earned.  Performance Periods may
overlap and Participants may participate simultaneously with respect to Stock
Bonuses that are subject to different Performance Periods and different
performance goals and other criteria.  The number of Shares may be fixed or may
vary in
<PAGE>

accordance with such performance goals and criteria as may be determined by the
Committee. The Committee may adjust the performance goals applicable to the
Stock Bonuses to take into account changes in law and accounting or tax rules
and to make such adjustments as the Committee deems necessary or appropriate to
reflect the impact of extraordinary or unusual items, events or circumstances to
avoid windfalls or hardships.

     9.3  Form of Payment.  The earned portion of a Stock Bonus may be paid to
          ---------------
the Participant by the Company either currently or on a deferred basis, with
such interest or dividend equivalent, if any, as the Committee may determine.
Payment may be made in the form of cash or whole Shares or a combination
thereof, either in a lump sum payment or in installments, all as the Committee
will determine.

10.  PAYMENT FOR SHARE PURCHASES.

     10.1 Payment.  Payment for Shares purchased pursuant to this Plan may be
          -------
made in cash (by check) or, where expressly approved for the Participant by the
Committee and where permitted by law:

          (a) by cancellation of indebtedness of the Company to the Participant;

          (b) by surrender of shares that either: (1) have been owned by the
Participant for more than six (6) months and have been paid for within the
meaning of SEC Rule 144 (and, if such shares were purchased from the Company by
use of a promissory note, such note has been fully paid with respect to such
shares); or (2) were obtained by the Participant in the public market;

          (c) by tender of a full recourse promissory note having such terms as
may be approved by the Committee and bearing interest at a rate sufficient to
avoid imputation of income under Sections 483 and 1274 of the Code; provided,
however, that Participants who are not employees or directors of the Company
will not be entitled to purchase Shares with a promissory note unless the note
is adequately secured by collateral other than the Shares;

          (d) by waiver of compensation due or accrued to the Participant for
services rendered;

          (e) with respect only to purchases upon exercise of an Option, and
provided that a public market for the Company's stock exists:

              (1) through a "same day sale" commitment from the Participant and
a broker-dealer that is a member of the National Association of Securities
Dealers (an "NASD Dealer") whereby the Participant irrevocably elects to
exercise the Option and to sell a portion of the Shares so purchased to pay for
the Exercise Price, and
<PAGE>

whereby the NASD Dealer irrevocably commits upon receipt of such Shares to
forward the Exercise Price directly to the Company; or

              (2) through a "margin" commitment from the Participant and a NASD
Dealer whereby the Participant irrevocably elects to exercise the Option and to
pledge the Shares so purchased to the NASD Dealer in a margin account as
security for a loan from the NASD Dealer in the amount of the Exercise Price,
and whereby the NASD Dealer irrevocably commits upon receipt of such Shares to
forward the Exercise Price directly to the Company; or

          (f) by any combination of the foregoing.

     10.2  Loan Guarantees. The Committee may help the Participant pay for
           ---------------
Shares purchased under this Plan by authorizing a guarantee by the Company of a
third-party loan to the Participant.

11.  WITHHOLDING TAXES.

     11.1  Withholding Generally.  Whenever Shares are to be issued in
           ---------------------
satisfaction of Awards granted under this Plan, the Company may require the
Participant to remit to the Company an amount sufficient to satisfy federal,
state and local withholding tax requirements prior to the delivery of any
certificate or certificates for such Shares.  Whenever, under this Plan,
payments in satisfaction of Awards are to be made in cash, such payment will be
net of an amount sufficient to satisfy federal, state, and local withholding tax
requirements.

     11.2  Stock Withholding.  When, under applicable tax laws, a participant
           -----------------
incurs tax liability in connection with the exercise or vesting of any Award
that is subject to tax withholding and the Participant is obligated to pay the
Company the amount required to be withheld, the Committee may allow the
Participant to satisfy the minimum withholding tax obligation by electing to
have the Company withhold from the Shares to be issued that number of Shares
having a Fair Market Value equal to the minimum amount required to be withheld,
determined on the date that the amount of tax to be withheld is to be
determined.  All elections by a Participant to have Shares withheld for this
purpose will be made in accordance with the requirements established by the
Committee and will be in writing in a form acceptable to the Committee.

12.  PRIVILEGES OF STOCK OWNERSHIP.

     12.1  Voting and Dividends.  No Participant will have any of the rights of
           --------------------
a stockholder with respect to any Shares until the Shares are issued to the
Participant.  After Shares are issued to the Participant, the Participant will
be a stockholder and will have all the rights of a stockholder with respect to
such Shares, including the right to vote and receive all dividends or other
distributions made or paid with respect to such Shares;
<PAGE>

provided, that if such Shares are Restricted Stock, then any new, additional or
different securities the Participant may become entitled to receive with respect
to such Shares by virtue of a stock dividend, stock split or any other change in
the corporate or capital structure of the Company will be subject to the same
restrictions as the Restricted Stock.

     12.2  Financial Statements.  The Company will provide financial statements
           --------------------
to each Participant prior to such Participant's purchase of Shares under this
Plan, and to each Participant annually during the period such Participant has
Awards outstanding; provided, however, the Company will not be required to
provide such financial statements to Participants whose services in connection
with the Company assure them access to equivalent information.

13.  NON-TRANSFERABILITY OF AWARDS.

     Awards granted under this Plan, and any interest therein, will not be
transferable or assignable by the Participant, and may not be made subject to
execution, attachment or similar process, other than by will or by the laws of
descent and distribution.  During the lifetime of the Participant an Award will
be exercisable only by the Participant.  During the lifetime of the Participant,
any elections with respect to an Award may be made only by the Participant
unless otherwise determined by the Committee and set forth in the Award
Agreement with respect to Awards that are not ISOs.

14.  CERTIFICATES.

     All certificates for Shares or other securities delivered under this Plan
will be subject to such stop transfer orders, legends and other restrictions as
the Committee may deem necessary or advisable, including restrictions under any
applicable federal, state or foreign securities law, or any rules, regulations
and other requirements of the SEC or any stock exchange or automated quotation
system upon which the Shares may be listed or quoted.

15.  ESCROW; PLEDGE OF SHARES.

     To enforce any restrictions on a Participant's Shares, the Committee may
require the Participant to deposit all certificates representing Shares,
together with stock powers or other instruments of transfer approved by the
Committee appropriately endorsed in blank, with the Company or an agent
designated by the Company to hold in escrow until such restrictions have lapsed
or terminated, and the Committee may cause a legend or legends referencing such
restrictions to be placed on the certificates.  Any Participant who is permitted
to execute a promissory note as partial or full consideration for the purchase
of Shares under this Plan will be required to pledge and deposit with the
Company all or part of the Shares so purchased as collateral to secure the
payment of the Participant's obligation to the Company under the promissory
note; provided, however, that the Committee may require or accept other or
additional forms of collateral to secure
<PAGE>

the payment of such obligation and, in any event, the Company will have full
recourse against the Participant under the promissory note notwithstanding any
pledge of the Participant's Shares or other collateral. In connection with any
pledge of the Shares, the Participant will be required to execute and deliver a
written pledge agreement in such form as the Committee will from time to time
approve. The Shares purchased with the promissory note may be released from the
pledge on a pro rata basis as the promissory note is paid.

16.  EXCHANGE AND BUYOUT OF AWARDS.

     The Committee may, at any time or from time to time, authorize the Company,
with the consent of the respective Participants, to issue new Awards in exchange
for the surrender and cancellation of any or all outstanding Awards.  The
Committee may at any time buy from a Participant an Award previously granted
with payment in cash, Shares (including Restricted Stock) or other
consideration, based on such terms and conditions as the Committee and the
Participant may agree.

17.  SECURITIES LAW AND OTHER REGULATORY COMPLIANCE.

     An Award will not be effective unless such Award is in compliance with all
applicable federal and state securities laws, rules and regulations of any
governmental body, and the requirements of any stock exchange or automated
quotation system upon which the Shares may then be listed or quoted, as they are
in effect on the date of grant of the Award and also on the date of exercise or
other issuance. Notwithstanding any other provision in this Plan, the Company
will have no obligation to issue or deliver certificates for Shares under this
Plan prior to: (a) obtaining any approvals from governmental agencies that the
Company determines are necessary or advisable; and/or (b) completion of any
registration or other qualification of such Shares under any state or federal
law or ruling of any governmental body that the Company determines to be
necessary or advisable.  The Company will be under no obligation to register the
Shares with the SEC or to effect compliance with the registration, qualification
or listing requirements of any state securities laws, stock exchange or
automated quotation system, and the Company will have no liability for any
inability or failure to do so.

18.  NO OBLIGATION TO EMPLOY.

     Nothing in this Plan or any Award granted under this Plan will confer or be
deemed to confer on any Participant any right to continue in the employ of, or
to continue any other relationship with, the Company or any Parent or Subsidiary
of the Company or limit in any way the right of the Company or any Parent or
Subsidiary of the Company to terminate Participant's employment or other
relationship at any time, with or without cause.
<PAGE>

19.  CORPORATE TRANSACTIONS.

     19.1  Assumption or Replacement of Awards by Successor.  In the event of
           ------------------------------------------------
(a) a dissolution or liquidation of the Company, (b) a merger or consolidation
in which the Company is not the surviving corporation (other than a merger or
consolidation with a wholly-owned subsidiary, a reincorporation of the Company
in a different jurisdiction, or other transaction in which there is no
substantial change in the stockholders of the Company or their relative stock
holdings and the Awards granted under this Plan are assumed, converted or
replaced by the successor corporation, which assumption will be binding on all
Participants), (c) a merger in which the Company is the surviving corporation
but after which the stockholders of the Company immediately prior to such merger
(other than any stockholder that merges, or which owns or controls another
corporation that merges, with the Company in such merger) cease to own their
shares or other equity interest in the Company, (d) the sale of substantially
all of the assets of the Company, or (e) the acquisition, sale, or transfer of
more than 50% of the outstanding shares of the Company by tender offer or
similar transaction, any or all outstanding Awards may be assumed, converted or
replaced by the successor corporation (if any), which assumption, conversion or
replacement will be binding on all Participants.  In the alternative, the
successor corporation may substitute equivalent Awards or provide substantially
similar consideration to Participants as was provided to stockholders (after
taking into account the existing provisions of the Awards).  The successor
corporation may also issue, in place of outstanding Shares of the Company held
by the Participant, substantially similar shares or other property subject to
repurchase restrictions no less favorable to the Participant.  In the event such
successor corporation (if any) refuses to assume or substitute Awards, as
provided above, pursuant to a transaction described in this Subsection 19.1,
such Awards will expire on such transaction at such time and on such conditions
as the Committee will determine.  Notwithstanding anything in this Plan to the
contrary, the Committee may provide that the vesting of any or all Awards
granted pursuant to this Plan will accelerate upon a transaction described in
this Section 19.  If the Committee exercises such discretion with respect to
Options, such Options will become exercisable in full prior to the consummation
of such event at such time and on such conditions as the Committee determines,
and if such Options are not exercised prior to the consummation of the corporate
transaction, they shall terminate at such time as determined by the Committee.

     19.2  Other Treatment of Awards.  Subject to any greater rights granted to
           -------------------------
Participants under the foregoing provisions of this Section 19, in the event of
the occurrence of any transaction described in Section 19.1, any outstanding
Awards will be treated as provided in the applicable agreement or plan of
merger, consolidation, dissolution, liquidation, or sale of assets.

     19.3  Assumption of Awards by the Company.  The Company, from time to time,
           -----------------------------------
also may substitute or assume outstanding awards granted by another company,
whether in connection with an acquisition of such other company or otherwise, by
either; (a) granting an Award under this Plan in substitution of such other
company's award; or
<PAGE>

(b) assuming such award as if it had been granted under this Plan if the terms
of such assumed award could be applied to an Award granted under this Plan. Such
substitution or assumption will be permissible if the holder of the substituted
or assumed award would have been eligible to be granted an Award under this Plan
if the other company had applied the rules of this Plan to such grant. In the
event the Company assumes an award granted by another company, the terms and
conditions of such award will remain unchanged (except that the exercise price
and the number and nature of Shares issuable upon exercise of any such option
will be adjusted appropriately pursuant to Section 424(a) of the Code). In the
event the Company elects to grant a new Option rather than assuming an existing
option, such new Option may be granted with a similarly adjusted Exercise Price.

20.  ADOPTION AND EFFECTIVE DATE.

     This Amendment and Restatement of the ARCA CORP. 1999 Dual Stock Option
Plan is effective as of July 24, 2001, the date it was adopted by the Board.

21.  TERM OF PLAN/GOVERNING LAW.

     Unless earlier terminated as provided herein, this Plan will terminate on
June 28, 2009.  This Plan and all agreements thereunder shall be governed by and
construed in accordance with the laws of the State of California.

22.  AMENDMENT OR TERMINATION OF PLAN.

     The Board may at any time terminate or amend this Plan in any respect,
including without limitation amendment of any form of Award Agreement or
instrument to be executed pursuant to this Plan; provided, however, that the
Board will not, without the approval of the stockholders of the Company, amend
this Plan in any manner that requires such stockholder approval.

23.  NONEXCLUSIVITY OF THE PLAN.

     Neither the adoption of this Plan by the Board, the submission of this Plan
to the stockholders of the Company for approval, nor any provision of this Plan
will be construed as creating any limitations on the power of the Board to adopt
such additional compensation arrangements as it may deem desirable, including,
without limitation, the granting of stock options and bonuses otherwise than
under this Plan, and such arrangements may be either generally applicable or
applicable only in specific cases.
<PAGE>

24.  ACTION BY COMMITTEE.

     Any action permitted or required to be taken by the Committee or any
decision or determination permitted or required to be made by the Committee
pursuant to this Plan shall be taken or made in the Committee's sole and
absolute discretion.

                   *****************************************<PAGE>

                                                                    Exhibit 10.4
                                                                REDACTED VERSION

                            ALBUMIN SUPPLY AGREEMENT

     *** Confidential treatment has been requested as to certain portions of
     this agreement.  Such omitted confidential information has been designated
     by an asterisk and has been filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
     Act of 1934, as amended, and the Commission's rules and regulations
     promulgated under the Freedom of Information Act, pursuant to a request for
     confidential treatment. ***

In Barcelona on this 22 day of June 1999.

                                 BY AND BETWEEN

SERACARE INC., a corporation of USA nationality, with address at 1926 Century
Park East, Suite 1970, Los Angeles, California, USA, represented by Mr. Barry D.
Plost, by virtue of his position as Chairman/CEO (hereinafter referred to as
SERACARE), party to the first part.

INSTITUTO GRIFOLS, S.A., a corporation of Spanish nationality, with address at
Poligono Industrial Levante, Calle Can Guasch, s/n. 08150 Parets del Valles,
Barcelona, Spain, represented by Mr. Javier Jorba Ribes, by virtue of his
position as General Manager, (Hereinafter referred to as GRIFOLS), party of the
second part.

                                    WHEREAS

I.   SERACARE is a corporation, which main activity is as a collector of plasma,
     distributor of therapeutic and diagnostic plasma derived products, and as a
     manufacturer of diagnostic products.

                                       1
<PAGE>

II.  GRIFOLS is a corporation, which main activity is the manufacturing and
     commercialization of Hemoderivatives, including Human Albumin, which are
     manufactured in its premises located in Parets del Valles.

III. GRIFOLS declares that its Human Albumin complies with the technical
     specifications that are detailed in Annex 1 attached hereto, and has all
     the necessary and required permits.

IV.  That both parties know that GRIFOLS Human Albumin is manufactured for its
     direct use and only in accordance with the product indications described in
     Annex 2 attached hereto.

V.   GRIFOLS is willing to supply and SERACARE to acquire, Human Albumin
     (hereinafter referred to as Albumin), due to which, both parties
     recognizing in each other enough legal capacity, agree to enter into the
     present Albumin Supply Agreement in accordance with the following.

                                    CLAUSES

FIRST -  Constitutes the object of the present Agreement, the supply to SERACARE
-------
of Human Albumin manufactured by GRIFOLS, to be sold by SERACARE to third
parties, which may only use said Human Albumin as raw material in its production
of certain products, and never for direct use, in accordance with the provisions
of this Agreement.

                                       2
<PAGE>

SECOND -  Due to the special technical specifications and quality controls that
--------
the Albumin has to comply with, the parties agree that all the Albumin supplied
by GRIFOLS to SERACARE will have a certified batch release from GRIFOLS.

THIRD -  The Albumin supplied by GRIFOLS to SERACARE will be used by any third
-------
party only as raw material, for the purpose of manufacturing products listed in
Annex 3.  No other use different from this, including its human use, is covered
by the present Agreement.

The Albumin supplied by GRIFOLS to SERACARE will not be mixed in the
manufacturing process of the products listed in Annex 3 carried out by any third
party with any other product of human origin.

GRIFOLS shall have the right, with prior notification of 24 hours, to require
SERACARE to inspect any third parties' manufacturing facilities and records in
order to verify the correct use of the Albumin supplied/sold by SERACARE to this
third party in accordance with the provisions of the present Agreement.

FOURTH -  The quality and technical specifications of the Albumin supplied by
--------
GRIFOLS to SERACARE, as detailed in Annex 1.

The quality and technical specifications, may be changed and/or modified, at
GRIFOLS' requirement, in order to comply with any new legislation in force
and/or new controls or test methods.  Any change carried out in accordance will
be duly notified to SERACARE, which shall notify it to all third parties to whom
the Albumin has been supplied/sold.

                                       3
<PAGE>

Every shipment of Albumin will be shipped together with all the mandatory and/or
legal documents, as well as any other documents that may be required.

FIFTH -  SERACARE will acquire from GRIFOLS the annual quantities established in
-------
Annex 4.  Both parties, on a yearly basis, will fix these minimum annual
quantities, as well as the Product price, which will also be included in said
Annex.

In the event that / new test and/or control is required, as stated in Clause
Fifth hereinabove, GRIFOLS and SERACARE shall mutually agree to renegotiate the
prices set forth in this Agreement.

SIXTH -  Payment of the Albumin delivered by GRIFOLS to SERACARE would be
-------
payable 30 days after reception by SERACARE in its premises in Oceanside, CA,
USA.

SEVENTH -  The Albumin will be shipped and packed in accordance with the
---------
specifications set forth in Annex 5 to the present Agreement.

EIGHTH -  For the event that the Albumin supplied by GRIFOLS to SERACARE is
--------
object of a product recall carried out by GRIFOLS, GRIFOLS will be responsible
only for its reposition with new Albumin.

Due to the use that third parties shall give to the Albumin, which will be as
raw material for manufacturing products listed in Annex 3 which is different and
not specified in the Product indications given by GRIFOLS, SERACARE and/or any
third party will be solely responsible for its use in accordance with the
present Agreement, and will hold GRIFOLS harmless of any

                                       4
<PAGE>

circumstances derived from the use that SERACARE and/or any third party will
give to the Albumin.

NINTH -  SERACARE declares that it has a product liability insurance covering
-------
the products, for an amount of $US 5,000,000 and takes the commitment to have
such insurance coverage while the present Agreement is in force and the products
manufactured using the Albumin have not expired, and will also require that any
third party using the Albumin has a product liability insurance in the same
terms and conditions.

TENTH -  All information disclosed by GRIFOLS to SERACARE concerning any aspect
-------
of Albumin, including discussions with Regulatory Authorities, shall be
considered as Confidential Information under this Agreement.

The party receiving the Confidential Information:

1.  Will not disclose the Confidential Information to any third party, except as
    required by the Regulatory Authorities strictly for the purposes of this
    Agreement.

2.  Will limit disclosure of the Confidential Information to its employees and
    agents who, under obligation of confidentiality, have a need to know of it
    for the purposes of this Agreement.

3.  Will make no use of the received Confidential Information other than to
    fulfill the purposes of this Agreement.

                                       5
<PAGE>

4.  On termination of this Agreement, will return all such Confidential
    Information to the disclosing party, without retaining any copy or extract
    thereof.

The following will be exempt from the obligation of this Article:

a)  Confidential Information which is now, or which becomes, part of the public
    domain without involvement of the receiving party.

b)  Confidential Information which the receiving party can demonstrate by
    competent proof was known to it before being received from the disclosing
    party.

c)  Confidential Information which becomes available to the receiving party from
    a third party under no obligation of confidentiality to the disclosing
    party.

The obligations of this article shall continue after termination of this
Agreement.

ELEVENTH -  SERACARE shall, prior to any sale of Albumin to any third party,
----------
inform GRIFOLS of the identity of said third party, as well as sign an agreement
with this third party that shall cover the following:

-  Use that this third party may do of the Albumin, which is as detailed in the
   manufacturing of products listed in Annex 3.

-  Manufacturing information by which this third party has to inform SERACARE
   and GRIFOLS of the lot numbers of the products manufactured using GRIFOLS
   Albumin.

-  Product liability insurance as foreseen in Clause Ninth of the present
   Agreement.

                                       6
<PAGE>

-  Signature of a Confidential Disclosure Agreement between said third party and
   GRIFOLS, which will be that attached as enclosure 6 hereto.

-  Responsibility Clause identical to that foreseen in Clause Eighth of the
   present Agreement.

-  Force Majeure Clause identical to that foreseen in Clause Thirteenth of the
   present Agreement.

-  Rescission/termination clause, which covers any breach of the clauses of the
   Agreement by the third party, especially if the Albumin is not used as raw
   material in the manufacturing of products listed in Annex 3, and a different
   use is given to it.

-  Clause including that SERACARE shall have the right, with a prior
   notification of 24 hours, to inspect the third parties' manufacturing
   facilities and records, in order to verify the correct use of the Albumin
   supplied by GRIFOLS in accordance with the provisions of the present
   Agreement.

TWELFTH -  The duration of the present Agreement will be until 31st December
---------
1999, and will start on the date of its signature.  The Agreement will be
automatically renewed for one-year periods if neither party denounces it three
months before its expiry.

THIRTEENTH -  Neither party shall be liable for non-performance of this
------------
Agreement due to Force Majeure.  Force Majeure will have the meaning stated
below under (a):

                                       7
<PAGE>

a)  Strikes, lockouts, other industrial disturbances, rebellions, mutinies,
    epidemics, landslides, lightning, earthquakes, fires, storms, floods,
    sinking, drought, civil disturbances, explosions, act or decisions of duly
    constituted municipal, state or National Governmental Authorities or of
    Courts of Law, impossibility to obtain supplies, fuel or other required
    materials, or any other causes similar or completely different, all beyond
    the control of the Party pleading Force Majeure preventing the Party from
    performing its rights and obligations and not to be overcome by due
    diligence of such Party.

b)  The Parties agree that if either of them find themselves wholly or partly
    unable to fulfill their respective obligations in this Agreement by reason
    of Force Majeure, the Party pleading Force Majeure will as soon as possible
    notify the other Party of its inability to perform giving detailed
    explanation of the occurrence which excuses performance. If said notice is
    given, the performance of the notifying party shall be abated for so long as
    performance may be prevented by Force Majeure. A Party unable to perform due
    to Force Majeure shall resume fulfilling its obligations, including making
    the due payments, after the Force Majeure has ceased. All terms will be
    extended by the time period the Force Majeure has lasted.

FOURTEENTH -  The present Agreement will be terminated and will become null due
------------
to any of the following reasons:

a)  Mutual agreement.

b)  Those fixed by law.

                                       8
<PAGE>

c)  With thirty (30) days notice if the other party shall default in the
    performance or observation of any material provisions of this Agreement and
    shall fail to cure such default within sixty (60) days after notice from
    such party, and the non-defaulting party shall reserve a right to seek a
    remedy available under the applicable laws.

d)  If any party falls into suspension of payments or becomes bankrupt.

e)  Not meeting payments due.

f)  Any substantial change in the ownership in any of the parties which may give
    rise to a change in the political control of the Company, or the
    participation through the acquisition of shares by a direct competitor of
    any of the parties.

FIFTEENTH -
-----------

a)  Any notice required or provided for by the terms of this Agreement shall be
    made in writing and shall be sent by registered mail postage prepaid or by
    telex or by facsimile properly addressed in accordance with the addresses
    first above given or to such other addresses as the parties may at a later
    date advise. The effective date of this notice shall be six (6) days after
    the date of sending such notice.

b)  This Agreement constitute the entire agreement between the parties
    concerning the subject matter hereof. None of the terms of this Agreement
    shall be amended or modified except in writing signed by the parties hereto.
    The headings used in this Agreement are only meant for easy reading of the
    Agreement.

                                       9
<PAGE>

c)  Provisions of this Agreement are separate and divisible and the invalidity
    or unenforceability of any part shall not affect the validity or
    enforceability of any remaining part or parts, all of which shall remain in
    full force and effect. However, the parties agree to substitute any invalid
    or unenforceable provision by valid and enforceable arrangement which
    achieves to the greatest extent possible the financial balance and mutual
    understanding already established between the parties.

SIXTEENTH -  Any dispute, controversy or difference that may arise from the
-----------
interpretation or in connection with the present Agreement or as the compliance
of any other obligations contained herein, shall be submitted to arbitration
held in Barcelona (Spain), in the "Tribunal Arbitral de Barcelona" according to
its rules.  The award rendered in any such arbitration shall be final and
binding upon the parties hereto.

SEVENTEENTH -  The parties agree that the present document is a commercial
-------------
agreement and is ruled by the Clauses contained herein, and shall be governed by
the laws of Spain, by Spanish commercial usage or, in its case, by the Spanish
Civil Code.

In witness whereof, the present Agreement is signed in duplicate in the place
and date first written above.

INSTITUTO GRIFOLS, S.A.                 SERACARE INC.

/s/ Javier Jorba Ribes                  /s/ Barry D. Plost

                                       10
<PAGE>

                            LIST OF OMITTED ANNEXES

The following Annexes to the Albumin Supply Agreement have been omitted from
this Exhibit and shall be furnished to the Commission upon request:

Annex      Document
-----      --------

2          USA Package Insert

3          Human Albumin as Raw Material

5          Shipment Information

6          Confidential Disclosure Agreement
<PAGE>

                                    ANNEX 1

                                      ***

_________________
*** Confidential information omitted and filed separately with the Securities
    and Exchange Commission.
<PAGE>

                                    ANNEX 4

                             HUMAN ALBUMIN GRIFOLS

                              QUANTITIES AND PRICE

-  The quantities established for the year 1999 will be in the range of Ten
   Thousand (10,000)* - Twelve Thousand (12,000) vials per month.

-  Product price:

   -  Human Albumin Grifols at *** per gram FOB Barcelona.

_________________
*** Confidential information omitted and filed separately with the Securities
    and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]